Jan Volavka1, Pál Czobor2, Leslie Citrome3, Richard A Van Dorn4. 1. 1Department of Psychiatry,New York University School of Medicine,New York,New York,USA. 2. 2Department of Psychiatry and Psychotherapy,Semmelweis University,Budapest,Hungary. 3. 3Department of Psychiatry and Behavioral Sciences,New York Medical College,Valhalla,New York,USA. 4. 4Research Triangle Institute International,Research Triangle Park,Durham,North Carolina,USA.
Abstract
INTRODUCTION: Aggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia. METHODS: We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility itemin a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline. RESULTS: The primary analysis of hostility indicated an effect of difference between treatments (F(4,1487) = 7.78, P < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6. DISCUSSION: Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride. CONCLUSION:Olanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.
RCT Entities:
INTRODUCTION:Aggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia. METHODS: We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline. RESULTS: The primary analysis of hostility indicated an effect of difference between treatments (F(4,1487) = 7.78, P < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6. DISCUSSION: Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride. CONCLUSION:Olanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.
Authors: L Citrome; J Volavka; P Czobor; B Sheitman; J P Lindenmayer; J McEvoy; T B Cooper; M Chakos; J A Lieberman Journal: Psychiatr Serv Date: 2001-11 Impact factor: 3.084
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman Journal: Schizophr Bull Date: 2003 Impact factor: 9.306
Authors: Kiersten L Johnson; Sarah L Desmarais; Stephen J Tueller; Kevin J Grimm; Marvin S Swartz; Richard A Van Dorn Journal: Psychiatry Res Date: 2016-09-26 Impact factor: 3.222
Authors: G Fond; L Boyer; M Favez; L Brunel; B Aouizerate; F Berna; D Capdevielle; I Chereau; J M Dorey; C Dubertret; C Faget; F Gabayet; H Laouamri; C Lancon; Y Le Strat; D Misdrahi; R Rey; C Passerieux; A Schandrin; F Schurhoff; A M Tronche; M Urbach; P Vidalhet; P M Llorca; A Pelissolo Journal: Psychopharmacology (Berl) Date: 2015-12-03 Impact factor: 4.530
Authors: Leslie Citrome; Joseph P McEvoy; Mark S Todtenkopf; David McDonnell; Peter J Weiden Journal: Neuropsychiatr Dis Treat Date: 2019-09-05 Impact factor: 2.570
Authors: E di Giacomo; A Stefana; V Candini; G Bianconi; L Canal; M Clerici; G Conte; M T Ferla; L Iozzino; G Sbravati; G Tura; R Micciolo; G de Girolamo Journal: Int J Neuropsychopharmacol Date: 2020-05-27 Impact factor: 5.176